Related references
Note: Only part of the references are listed.Protein Phosphatase Magnesium-Dependent 1δ (PPM1D) mRNA Expression Is a Prognosis Marker for Hepatocellular Carcinoma
Guang-Bing Li et al.
PLOS ONE (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Combination of Radiotherapy and Adenovirus-Mediated p53 Gene Therapy for MDM2-Overexpressing Hepatocellular Carcinoma
Woong Sub Koom et al.
JOURNAL OF RADIATION RESEARCH (2012)
Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival
Naoyuki Satoh et al.
CANCER SCIENCE (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC
Liangan Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
PPM1D Silencing by Lentiviral-mediated RNA Interference Inhibits Proliferation and Invasion of Human Glioma Cells
Peng Wang et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2011)
MicroRNA in lung cancer diagnostics and treatment
Marcin Skrzypski et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2011)
Involvement of microRNAs in lung cancer biology and therapy
Xi Liu et al.
TRANSLATIONAL RESEARCH (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
Maryou B. Lambros et al.
MODERN PATHOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
shRNA technology Investigating Ras-dependent cancer
Erica V. Stein et al.
CANCER BIOLOGY & THERAPY (2009)
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
David S. P. Tan et al.
CLINICAL CANCER RESEARCH (2009)
The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways
Xiongbin Lu et al.
CANCER AND METASTASIS REVIEWS (2008)
Identification of differentially expressed genes after PPM1D silencing in breast cancer
Jenita Parssinen et al.
CANCER LETTERS (2008)
Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D
Robert C. Castellino et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome
Panayiotis Loukopoulos et al.
CANCER SCIENCE (2007)
The molecular epidemiology of lung cancer
Ann G. Schwartz et al.
CARCINOGENESIS (2007)
被撤回的出版物: 100 years of lung cancer (Retracted article. See vol 103, pg 1244, 2009)
Michaet Pirozynski
RESPIRATORY MEDICINE (2006)
Wip1 phosphatase modulates ATM-dependent signaling pathways
Sathyavageeswaran Shreeram et al.
MOLECULAR CELL (2006)
Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice
Bonnie Nannenga et al.
MOLECULAR CARCINOGENESIS (2006)
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase
H. Fujimoto et al.
CELL DEATH AND DIFFERENTIATION (2006)
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
XB Lu et al.
GENES & DEVELOPMENT (2005)
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway
DV Bulavin et al.
NATURE GENETICS (2004)
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity
DV Bulavin et al.
NATURE GENETICS (2002)
Share Paper
